Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774446 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
A Phase 2 study of Cushing Disease, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03774446: Recruiting Phase 2 study of Cushing Disease, sponsored by Cedars-Sinai Medical Center.
NCT03774446 is a Phase 2 study of Cushing Disease that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 13 participants, below the 391-participant average among 8 other Cushing Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03774446, a Phase 2 study of Cushing Disease, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
Conditions Studied
Interventions
- DRUG Seliciclib
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT03774446 shows while recruiting
NCT03774446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 391-participant average among 8 other Cushing Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cushing Disease appearing as the primary indexed condition, and to 1 intervention - of which Seliciclib is the first listed.
NCT03774446 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03774446 about?
NCT03774446 is a clinical study titled "Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease". This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)
What is the current status of trial NCT03774446?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-11-02. Estimated completion is 2026-08.
What conditions does trial NCT03774446 study?
This clinical trial studies the following conditions: Cushing Disease.
What interventions are being tested in trial NCT03774446?
The interventions under investigation include: Seliciclib (DRUG).
Who is sponsoring clinical trial NCT03774446?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774446 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03774446's enrollment target sits among peer trials
13 9th of 8 the lowest of 8 other Cushing Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cushing Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
RECRUITING · Phase 2
-
Safety and Efficacy of LCI699 in Cushing's Disease Patients
COMPLETED · Phase 2
-
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
RECRUITING
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- NCT04879121 · 13 participants · Phase 2
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI